Votoplam

Phase 3Small molecule

Novartis

Votoplam is one of 18 small molecule programs targeting Huntington's Disease (HD). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Huntington's Disease (HD)Active, not recruiting

Huntington DiseaseRecruiting

Huntington's Disease (HD)Phase 2

Active, not recruiting

Huntington DiseasePhase 3

Recruiting

Competition

Competitive Landscape

19 competitors in Huntington Disease

#DrugCompanyPhaseTrials

Epidiolex

Dojolvi

Actigall

Risperdal

Minocin

Glucophage

Haldol

Tricor

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—10

Rilutek

AAzurity Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Active, not recruiting

Huntington's Disease (HD)

NCT06254482

Q2 2030

Phase 3Recruiting

Huntington Disease

NCT07326709

Clinical

Trials by Indication[1]

Huntington's Disease (HD)1 trial

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT06254482·144 enrolled

Huntington disease1 trial

A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

Recruiting· Novartis logo

Novartis·Phase 3·NCT07326709·770 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Votoplam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Votoplam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Votoplam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Votoplam

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Q2 2030

Trials by Indication[1]

Huntington's Disease (HD)1 trial

Huntington disease1 trial

References

Drug Info

Quick Facts

Related News